Share:
ProPath, the largest fully physician-owned pathology practice in the United States, today announced that Julia A. Bridge, M.D., a board-certified pathologist and geneticist with an extensive medical career and expertise in solid tumor molecular testing, has joined the ProPath team.
Dr. Bridge, who recently directed the Molecular Pathology Research Division at the Translational Genomics Research Institute in Phoenix, AZ, will be directing ProPath s fluorescence in situ hybridization (FISH) and cytogenetics team. She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPath s molecular pathology team. We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath. She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice. Her ability to interpret microscopic morphology in concert with her unsurpass
The University of Nebraska is seeking a proven, student-centered, inclusive leader with a deep understanding of the metropolitan mission to serve as the next chancellor of the University of Nebraska at Omaha, as described in a position profile announced today by NU System President Ted Carter.
The job description for UNO’s next chancellor, developed by a 14-member search committee following a series of public listening sessions in the fall, calls for an experienced, collaborative leader who will build strong relationships with UNO’s diverse constituencies as the university begins its next chapter of meeting the needs of its metropolitan area, the state, region and world.
Women physicians spend more time on citizenship tasks than their male colleagues news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
January 6, 2021
Western Iowa While select groups of Iowans are now getting COVID-19 vaccines developed by either Pfizer or Moderna, a third company’s vaccine is now going into the third phase of testing in Omaha-Council Bluffs.
Dr. Diana Florescu, an infectious diseases specialist at the University of Nebraska Medical Center, says they’re grateful and excited to be chosen as a site for this important work. Dr. Florescu says, “Our hope is that this vaccine will prevent people from developing severe disease and decrease the chances of being hospitalized or dying.”
The investigational vaccine was developed by Novavax, a biotechnology company headquartered in Maryland. The Omaha-based hospital plans to enroll up to one-thousand study participants from Nebraska and Iowa.
New UNO counterterrorism center will aid in Homeland Security s bioterrorism exercise in February fremonttribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fremonttribune.com Daily Mail and Mail on Sunday newspapers.